From the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia.
Address correspondence and reprint requests to Charles B. Nemeroff, MD, PhD, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Suite 4000 WMRB, Atlanta, GA 30322. E-mail: [email protected]
Received for publication April 17, 2004; revision received August 11, 2004.
In accordance with CME accreditation guidelines, author Charles B. Nemeroff disclosed that he has received research support from, served as a consultant for, and/or served on the speakers’ bureau for Acadia Pharmaceuticals, AFSP, AstraZeneca, Bristol-Myers-Squibb, Corcept, Cyberonics, Cypress Biosciences, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Merck, NARSAD, Neurocrine Biosciences, NIMH, Organon, Otsuka, Pfizer Pharmaceuticals, Sanofi, Somerset, Stanley Foundation/NAMI, Wyeth-Ayerst, and Abbott Laboratories. He is a stockholder in Corcept and Neurocrine Biosciences. He is on the board of directors for American Foundation for Suicide Prevention (AFSP), Cypress Biosciences, George West Mental Health Foundation, Novadel Pharma, and the Heinz C. Prechter Fund for Manic Depression. He is supported by NIH grants MH-42088 MH-52899 and NCRR MOI-RR00039. The other author of this article disclosed no real or potential conflicts of interest.
